Key Points Telix administered the first U.S. commercial doses of Pixclara at medical centers in Indianapolis and Cleveland. Pixclara is the only FDA-approved radiopharmaceutical imaging…
September 09, 2026
Actuate Reports Preclinical Synergy for Elraglusib With RAS Inhibitors in Pancreatic Cancer
Key Points Actuate Therapeutics reported preclinical data showing that elraglusib enhanced the activity of two investigational RAS-targeted therapies in pancreatic cancer models. The studies tested…
September 09, 2026
Kazia Doses First Patient in Phase 2 Paxalisib Trial for Recurrent AT/RT Brain Cancer
Key Points Kazia Therapeutics dosed the first patient in PNOC035, a Phase 2 study of paxalisib plus gemcitabine for recurrent or progressive AT/RT. The study…
September 08, 2026
PDS Biotech Raises Up to $22.55 Million to Advance Cancer Drug Programs
Key Points PDS Biotechnology announced a PIPE financing of up to $22.55 million led by Nant Capital. The company expects an initial $11.55 million closing…
Key Points Adlai Nortye dosed the first patient in Australia in a global Phase 1 trial of AN4035. The U.S. FDA cleared the company’s IND…
August 26, 2026
FDA Approves Revolution Medicines’ Rasonque for Metastatic Pancreatic Cancer, Months Ahead of Schedule
Key Points The FDA approved daraxonrasib under the brand name Rasonque for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic…
Ahead of Nuvation Bio’s (NYSE: NUVB) second-quarter results, investors were looking for evidence that the company’s strong first quarter represented the beginning of a sustainable…
Key Points Citius Oncology, Inc. reports accelerating commercial momentum for LYMPHIR, its FDA‑approved treatment for cutaneous T‑cell lymphoma (CTCL). New U.S. institutions ordering LYMPHIR rose…